Abstract Library

#3812 Validation of NEP-D score as a prognostic index in bronchial carcinoid tumors

Introduction: The development of prognostic scores able to classify patients with Bronchial Carcinoid (BC) according to clinical outcomes may help guide treatment selection. The NEP- score was found to be useful to stratify survival probability in patients with well-differentiated neuroendocrine neoplasms (NENs). According to multiple factors (age, primary tumor site, presence of metastasis, Ki-67, presence of functioning status and prior surgical removal of the primary tumor) NEP- score stratifies patients into different risk groups. The NEP-score at diagnosis (NEP-D score) is a derived score that could be calculated at diagnosis and does not consider the appearance of new metastases during follow-up.

Conference:

Presenting Author:

Authors: Medici M, Gagliardi I, Zanata I, Borges de Souza P, Ambrosio M,

Keywords: Bronchial Carcinoid, Neuroendocrine neoplasm, NEP-Score, Prognosis, Survival,

#3416 MEN1 gene sequence variant C.[527 G> A] P.[ARG 176 GLN]: Is it pathogenic?

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare syndrome with a severe impact on quality of life of patients and their relatives and early diagnosis is mandatory. Many single-nucleotide polymorphisms of the MEN1 gene are reported, but only few are pathogenic.

Conference:

Presenting Author:

Authors: Zanata I, Crociara A, Ambrosio M, Bondanelli M, Aliberti L,

Keywords: MEN1, C.[527 G> A] P.[ARG 176 GLN], sequence variant,

#2983 Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids

Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). Metastatic BC having low to moderate mitotic count may still be treated with somatostatin analogues and mTOR inhibitors; however, TBC and ABC have been reported to respond very differently to therapy and an effective treatment algorithm is still lacking. TGF-β is known for its ability to activate mTOR pathway and induce epithelial mesenchymal transition, affecting cell pathophysiological capabilities such as proliferation, migration and tissue invasiveness.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Borges de Souza P

Authors: Borges de Souza P, Tagliatti V, Capobianco S, Ambrosio M, Chinnici S,

Keywords: Neuroendocrine neoplasms, bronchial carcinoids, TGF-β,

#1999 Study of Cell Cycle Protein Expression Pattern in Bronchial Carcinoids: A New Potential Target for Medical Therapy?

Introduction: Bronchial Carcinoids (BCs) are rare neuroendocrine neoplasms arising from respiratory epithelium. The only effective treatment option is surgery, but its efficacy is frequently limited by metastatic spread. Everolimus prolongs progression free survival but patients may develop resistance. Previous studies demonstrated that Everolimus reduces viability of NCI-H720 cells (Atypical Carcinoid) but not of NCI-H727 cells (Typical Carcinoid). Everolimus decreases Ciclyn D1 protein levels in both cell lines but NCI-H727 cells survive, indicating a derangement in cell cycle control.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Bresciani G, Riva E, Ambrosio M, Zatelli M,

Keywords: bronchial carcinoids, cell cycle, cyclins, cdks, target therapy, everolimus, dinaciclib, palbociclib,

#479 Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ambrosio M, Guerra A, Lupo S, Bondanelli M, Sartori S,

Keywords: Everolimus, GEP-NET, efficacy, side effects,